Re-evaluation of the role of postoperative radiotherapy and the impact of radiation dose for non-small-cell lung cancer using the National Cancer Database

Journal of Thoracic Oncology

Volumn 10, Issue 1, 2015, Pages 148-155

  Corso, Christopher D ^a,c   Rutter, Charles E ^a,c   Wilson, Lynn D ^a,c   Kim, Anthony W ^b,c   Decker, Roy H ^a,c   Husain, Zain A ^a,c  

^a Smilow Cancer Hospital   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c YALE CANCER CENTER   (United States)

Author keywords

National Cancer Database; Non small cell lung cancer; Postoperative radiotherapy

Indexed keywords

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EVALUATION; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LARGE CELL CARCINOMA; LARGE CELL LUNG CARCINOMA; LOBECTOMY; LUNG ADENOCARCINOMA; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; RADIATION DOSE; RADIATION RESPONSE; SQUAMOUS CELL LUNG CARCINOMA; THERAPY EFFECT; TREATMENT OUTCOME; ADJUVANT THERAPY; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; POSTOPERATIVE PERIOD; STATISTICS AND NUMERICAL DATA;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT;

EID: 84926408841     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000406     Document Type: Article

References (22)

1. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-3359.
2. PORT Meta-analysis Trialists Group. Postoperative radiotherapy for non-small cell lung cancer. Cochrane Database Syst Rev 2005(2):CD002142.
3. Machtay M, Kaiser LR, Glatstein E. Is meta-analysis really meta-physics? Chest 1999;116:539-542.
4. Douillard JY, Rosell R, De Lena M, Riggi M, Hurteloup P, Mahe MA. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: The adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial. Int J Radiat Oncol Biol Phys 2008;72:695-701.
5. Lally BE, Zelterman D, Colasanto JM, Haffty BG, Detterbeck FC, Wilson LD. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol 2006;24:2998-3006.
6. Wakelee HA, Stephenson P, Keller SM, et al; Eastern Cooperative Oncology Group Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590. Lung Cancer 2005;48:389-397.
7. Bogart JA, Aronowitz JN. Localized non-small small cell lung cancer: Adjuvant radiotherapy in the era of effective systemic therapy. Clin Cancer Res 2005;11:5004s-5010s.
8. Rutter CE, Corso CD, Park HS, et al. Increase in the use of lung stereotactic body radiotherapy without a preceding biopsy in the United States. Lung Cancer 2014;85:390-394.
9. Saji H, Tsuboi M, Yoshida K, et al. Prognostic impact of number of resected and involved lymph nodes at complete resection on survival in non-small cell lung cancer. J Thorac Oncol 2011;6:1865-1871.
10. Patel V, Shrager JB. Which patients with stage III non-small cell lung cancer should undergo surgical resection? Oncologist 2005;10:335-344.
11. Urban D, Bar J, Solomon B, Ball D. Lymph node ratio may predict the benefit of postoperative radiotherapy in non-small-cell lung cancer. J Thorac Oncol 2013;8:940-946.
12. Bekelman JE, Rosenzweig KE, Bach PB, Schrag D. Trends in the use of postoperative radiotherapy for resected non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006;66:492-499.
13. Machtay M, Lee JH, Shrager JB, Kaiser LR, Glatstein E. Risk of death from intercurrent disease is not excessively increased by modern postoperative radiotherapy for high-risk resected non-small-cell lung carcinoma. J Clin Oncol 2001;19:3912-3917.
14. Zhao L, Ji W, Ou G, et al. Risk factors for radiation-induced lung toxicity in patients with non-small cell lung cancer who received postoperative radiation therapy. Lung Cancer 2012;77:326-330.
15. Phlips P, Rocmans P, Vanderhoeft P, Van Houtte P. Postoperative radiotherapy after pneumonectomy: Impact of modern treatment facilities. Int J Radiat Oncol Biol Phys 1993;27:525-529.
16. Lally BE, Detterbeck FC, Geiger AM, et al. The risk of death from heart disease in patients with nonsmall cell lung cancer who receive postoperative radiotherapy: Analysis of the surveillance, epidemiology, and end results database. Cancer 2007;110:911-917.
17. Le Péchoux C. Role of postoperative radiotherapy in resected non-small cell lung cancer: A reassessment based on new data. Oncologist 2011;16:672-681.
18. Billiet C, Decaluwé H, Peeters S, et al. Modern post-operative radiotherapy for stage III non-small cell lung cancer may improve local control and survival: A meta-analysis. Radiother Oncol 2014;110:3-8.
19. Dai H, Hui Z, Ji W, et al. Postoperative radiotherapy for resected pathological stage IIIA-N2 non-small cell lung cancer: A retrospective study of 221 cases from a single institution. Oncologist 2011;16:641-650.
20. Scotti V, Meattini I, Saieva C, et al. Post-operative radiotherapy in N2 non-small cell lung cancer: A retrospective analysis of 175 patients. Radiother Oncol 2010;96:84-88.
21. Feng QF, Wang M, Wang LJ, et al. A study of postoperative radiotherapy in patients with non-small-cell lung cancer: A randomized trial. Int J Radiat Oncol Biol Phys 2000;47:925-929.
22. Paumier, A. Le Péchoux C. Post-operative radiation therapy. Transl Lung Cancer Res 2013;2:423-432.